Study guide

Contraceptive choice and missed pills

AMC CAT MCQ Examination AMC Part 1

Track your progress as you read

Finished sections get a check mark.

1 Acute Coronary Syndromes & ECG Localization

ACS recognition and ECG localisation Reperfusion and infarction complications

2 Heart Failure, Cardiogenic Shock & Cardiac Arrhythmias

Heart failure assessment and treatment Arrhythmias and conduction emergencies

3 Systemic Hypertension & Peripheral Vascular Disease

Blood pressure and cardiovascular risk Secondary hypertension and arterial disease

4 Valvular Heart Disease, Infective Endocarditis & Pericarditis

Aortic and mitral valve disease Endocarditis and pericardial emergencies

5 Asthma & COPD Acute Flares and Maintenance

Asthma and COPD diagnosis and maintenance Acute asthma and COPD exacerbations

6 Pneumonia, pleural disease and respiratory failure

Pneumonia and infected pleural collections Pulmonary embolism, effusions and pneumothorax Respiratory failure, ARDS and sepsis

7 GI bleeding, bowel inflammation and malabsorption

GI bleeding assessment and resuscitation Varices, ulcers, reflux and lower GI bleeding IBD patterns and severe colitis assessment IBD treatment, coeliac disease and IBS

8 Chronic Liver Disease, Cirrhosis Complications & Acute Hepatitis

Cirrhosis diagnosis and prognosis Decompensation, viral hepatitis and surveillance

9 Diabetes, thyroid and adrenal disease

Diabetes diagnosis and ongoing care DKA, HHS and complication monitoring Thyroid disease assessment Thyroid emergencies and adrenal disease

10 Acute Kidney Injury, Chronic Kidney Disease & Fluid/Electrolyte Emergencies

AKI and chronic kidney disease Potassium and sodium emergencies

11 Anaemias, Inflammatory Arthropathies & Geriatric Comprehensive Assessment

Anaemia, bruising and blood disorders Arthritis, autoimmune disease and geriatric care

12 Evaluation of the Acute Abdomen, Peritonitis & Appendicitis

Abdominal pain, peritonitis and resuscitation Appendicitis diagnosis and treatment Perforation and mesenteric ischaemia

13 Small and Large Bowel Obstruction & Colorectal Surgical Pathology

Small bowel obstruction Colonic obstruction, volvulus and cancer recognition Colorectal care, diverticulitis and anorectal symptoms

14 Gallbladder Disease, Biliary Tract Infections & Acute Pancreatitis

Gallstones and biliary obstruction Cholangitis and pancreatitis diagnosis Pancreatitis severity and treatment

15 Advanced Trauma Life Support, Primary Survey & Life-Threatening Thoracic Injuries

Trauma primary survey and adjuncts Chest trauma and immediate threats

16 Traumatic Brain Injury, Intracranial Haemorrhage & Spinal Cord Clearance

Head injury, imaging and haemorrhage Herniation and spinal cord injury

17 Major Fractures, Joint Dislocations & Acute Compartment Syndrome

Fracture assessment and open injuries Compartment syndrome, dislocations and pelvic injury

18 Thermal Burns, Haemorrhagic Shock Resuscitation & Surgical Wound Care

Burn assessment and fluid resuscitation Bleeding shock, wound care and tetanus

19 Aortic Aneurysms & Acute Arterial Limb Ischaemia

Aneurysm recognition and planned care Ruptured aneurysm and acute limb ischaemia

20 Urological Emergencies, Testicular Torsion & Haematuria Investigation

Retention, stones and obstructed infection Scrotal pain and haematuria

21 Preoperative Risk Stratification & Postoperative Surgical Complications

Preoperative assessment and medicines Postoperative complications and prevention

22 Early Pregnancy Bleeding, Ectopic Pregnancy & Antenatal Screening

Miscarriage and ectopic pregnancy Antenatal screening and early-pregnancy comparisons

23 Hypertensive Disorders of Pregnancy & Medical Complications in Pregnancy

Pregnancy hypertension and preeclampsia Eclampsia, HELLP and antepartum bleeding

24 Intrapartum Monitoring, Postpartum Haemorrhage & Obstetric Emergencies

Labour physiology and CTG assessment CTG response and postpartum haemorrhage Obstetric emergencies and preterm birth

25 Abnormal Uterine Bleeding, Pelvic Pain & Endometriosis

Abnormal bleeding and structural causes Endometrial sampling and endometriosis PCOS diagnosis and long-term care

26 Contraception, Emergency Contraception & Pregnancy Termination

Contraceptive choice and missed pills Emergency contraception and abortion

27 Australian Cervical Screening Program & Gynaecological Malignancies

Cervical screening and cervical cancer Endometrial and ovarian cancer

28 Neonatal Resuscitation, Congenital Conditions & Neonatal Jaundice

Newborn resuscitation, Apgar and cyanosis Neonatal jaundice assessment Jaundice treatment and congenital screening

29 Developmental Milestones, Growth Charts & Failure to Thrive

Developmental milestones Regression, autism and support Faltering growth and developmental comparisons

30 The Limping Child, Septic Arthritis vs Transient Synovitis & Paediatric Hip Conditions

Limp assessment and septic-joint risk Joint-infection management and Perthes disease SUFE and paediatric hip comparisons

31 Croup, Bronchiolitis, Paediatric Asthma & Anaphylaxis

Croup Bronchiolitis Paediatric asthma Paediatric anaphylaxis

32 Evaluation of the Febrile Child, Sepsis & Meningococcal Disease

Febrile neonates and young infants Meningococcal disease and paediatric sepsis Bacterial meningitis and CSF interpretation Kawasaki disease and follow-up

33 Paediatric Surgical Abdomen, Dehydration & Child Protection / Non-Accidental Injury

Pyloric stenosis Intussusception and dehydration Child protection and injury assessment

34 The Mental State Examination & Suicide Risk Stratification

Mental state examination and psychotic symptoms Suicide formulation and mental health law

35 Major Depressive Disorder, Bipolar Affective Disorder & Mood Stabilisers

Depression assessment and treatment Serotonin toxicity and bipolar presentations Mood stabilisers and ECT

36 Generalised Anxiety, Panic Disorder, PTSD & Obsessive-Compulsive Disorder

Anxiety, panic and agoraphobia OCD and trauma-related disorders

37 Schizophrenia, Acute Psychosis & Antipsychotic Management

Psychosis assessment and antipsychotics Clozapine and severe adverse effects

38 Substance Use Disorders & Acute Withdrawal Syndromes

Substance disorders and alcohol withdrawal Wernicke disease, opioids and stimulants

39 Delirium vs Dementia, Perinatal Mood Disorders & Paediatric Psychiatry

Delirium and dementia assessment Cognitive behaviour, perinatal and childhood psychiatry

40 Medicare, PBS, AHPRA & Good Medical Practice Framework

Australian health services and Medicare PBS access and professional registration Professional boundaries and notifications

41 Informed Consent (Rogers v Whitaker), Mental Capacity & Involuntary Treatment

Consent, material risks and young people Capacity, refusal and substitute decisions

42 Patient Privacy, Confidentiality Exceptions & Mandatory Notifications

Privacy, disclosure and child reporting Driving fitness and threat disclosure

43 First Nations health and preventive care

First Nations health, determinants and cultural safety Community care, Item 715 and CTG medicines Immunisation and cancer screening entry points Screening pathways and primary CVD prevention

44 Epidemiological Metrics, Clinical Study Designs & Notifiable Communicable Diseases

Epidemiology, calculations, bias and surveillance

45 Neurological presentations

Stroke, TIA and focal weakness Headache, facial pain and vertigo Seizures, collapse and altered consciousness Numbness, movement disorders and generalised weakness

46 Musculoskeletal pain

Back, neck, bone and soft tissue pain

47 Eye presentations

Altered vision and retinal disease Red eye, ocular injury and discharge

48 Ear, nose, throat and oral health

Ear pain, hearing loss and tinnitus Nasal problems, neck lumps, hoarseness and dysphagia Toothache, mouth symptoms, dry mouth and halitosis

49 Skin, hair and nails

Rash, itch, infection and skin ulcers Skin lesions, hair loss and nail abnormalities

50 Breast health and feeding

Breast lumps, discharge and breastfeeding problems

51 Sexual and reproductive presentations

Genital symptoms, discharge and pelvic infection Menopause, prolapse and urinary symptoms Infertility and sexual dysfunction

52 Palliative care and carers

The dying patient, symptoms and carers

53 Eating disorders and personality care

Eating disorders, obesity and weight change Personality difficulties, self-harm and complex care

54 Sleep presentations

Insomnia, snoring and daytime sleepiness

55 Poisoning, resuscitation and environmental emergencies

Poisoning, toxidromes and antidote decisions Cardiopulmonary arrest, choking and emergency help Bites, stings, heat, cold and drowning

56 Communication, rights and professional practice

Communication, handover, errors and complaints Healthcare rights, inclusive care and equitable access Certificates, deaths, CPD and supervision Telehealth, images, prescribing and doctors' health

57 Genetics, research and donation

Genetic testing, research and organ donation

58 Travel, fever and outbreaks

Fever, travellers and outbreak response

Contraceptive choice and missed pills

Key Takeaways Explain This Topic AI

Migraine with aura is a contraindication to combined hormonal contraception.

The Australian etonogestrel implant is licensed for three years.

Mirena's contraceptive duration differs from its heavy-bleeding and endometrial-protection indications.

Last updated: October 2026

Contraception, Emergency Contraception & Pregnancy Termination

Contraceptive eligibility: Use the current Australian clinical resource and the MEC framework it adopts, noting that WHO and UK classifications differ in detail. Core CHC contraindications include migraine with aura, severe hypertension and current breast cancer. Past disease, VTE on treatment and complicated diabetes need their specific category and circumstances rather than one universal label.

Long-Acting Reversible Contraception (LARC)

Long-acting reversible contraceptives (LARCs) are the most effective methods of reversible fertility control because their clinical efficacy does not depend on daily compliance, coital timing, or frequent administration. Australian national guidelines strongly advocate for LARCs as first-line options for all individuals seeking contraception, including nulliparous women and adolescents.

Etonogestrel Subdermal Implant (Implanon NXT)

Pharmacology & Duration : A single radiopaque rod ( 4 cm × 2 mm 4\text{ cm} \times 2\text{ mm} 4 cm × 2 mm ) containing 68 mg 68\text{ mg} 68 mg of etonogestrel (the active metabolite of desogestrel). Licensed in Australia for 3 years of continuous use.

Efficacy : The most effective reversible contraceptive available, with a failure rate of < 0.05 % < 0.05\% < 0.05% (higher efficacy than surgical sterilization).

Mechanism of Action :

Complete suppression of ovulation via inhibition of the mid-cycle luteinizing hormone (LH) surge.

Rapid thickening of cervical mucus, preventing sperm ascent into the upper reproductive tract.

Induction of an atrophic, hostile endometrial lining.

Bleeding Patterns & Clinical Management : Unscheduled bleeding is the most common reason for premature discontinuation (~20% of users experience amenorrhoea, ~50% experience infrequent or light bleeding, and ~20% to 30% experience frequent or prolonged bleeding). Management of bothersome prolonged bleeding includes ruling out pregnancy and sexually transmitted infections (STIs), followed by a 3-month course of low-dose combined oral contraceptive pills (COCP) or a short course of oral mefenamic acid ( 500 mg 500\text{ mg} 500 mg TDS) or tranexamic acid ( 1 g 1\text{ g} 1 g TDS) taken during bleeding episodes.

Fertility Return : Rapid return of fertility, with ovulatory cycles resuming within weeks of removal.

Levonorgestrel Intrauterine System (LNG-IUS)

Available Devices in Australia :

Mirena: Licensed for eight years of contraception and five years for heavy menstrual bleeding. Duration for endometrial protection during menopausal hormone therapy is a separate indication; confirm current Australian product information and specialist guidance.

Kyleena ( 19.5 mg 19.5\text{ mg} 19.5 mg LNG) : Smaller frame and narrower insertion tube (suitable for nulliparous individuals with a small cervical canal). Licensed for 5 years for contraception.

Mechanism of Action : Primarily a profound local progestogenic effect resulting in glandular endometrial atrophy and dense stromal decidualization, rendering the endometrium unreceptive to implantation. It also thickens cervical mucus. Most women continue to ovulate spontaneously because systemic progestogen absorption is minimal.

Clinical Indications : Extremely effective contraception (failure rate < 0.2 % < 0.2\% < 0.2% ). Mirena is the recognized medical first-line therapy for heavy menstrual bleeding, reducing objective menstrual blood loss by > 90 % > 90\% > 90% within 6 months, and is highly effective in managing pain associated with adenomyosis and endometriosis.

Copper Intrauterine Device (Cu-IUD)

Devices & Duration : TT380 Standard (licensed for 10 years ) and TT380 Short (licensed for 5 years ).

Copper-IUD EC: Copper impairs sperm function and prevents fertilisation; it does not terminate an established pregnancy. Timing is assessed against intercourse and estimated ovulation, with pregnancy exclusion and infection considerations before insertion.

Side Effects : Failure rate < 0.8 % < 0.8\% < 0.8% . Users frequently experience heavier menses, prolonged menstrual flow, and increased dysmenorrhoea. It is contraindicated in unexplained abnormal uterine bleeding, active pelvic infection, severe uterine anatomical distortion, and Wilson disease.

Combined hormonal methods: Discuss locally available formulations, contraindications, bleeding preferences and adherence. Do not assume every product licensed overseas is available in Australia.

Mechanism of Action

Oestrogen Component : Suppresses pituitary secretion of follicle-stimulating hormone (FSH), preventing dominant follicle selection and development.

Progestogen Component : Suppresses the mid-cycle LH surge, preventing ovulation. It also thickens cervical mucus to impede sperm penetration and induces endometrial atrophy.

MEC Category 1 : A condition for which there is no restriction for the use of the contraceptive method.

MEC Category 2 : A condition where the advantages of using the method generally outweigh the theoretical or proven risks.

MEC Category 3 : A condition where the theoretical or proven risks usually outweigh the advantages. Method is not recommended unless other methods are unavailable or unacceptable.

MEC Category 4 : A condition that represents an unacceptable health risk ( Absolute Contraindication ).

Absolute Contraindications (MEC 4) for Combined Hormonal Contraceptives

Migraine with Aura at Any Age : Conveys an unacceptably high relative and absolute risk of ischaemic stroke due to the synergistic prothrombotic and vasoconstrictive effects of exogenous oestrogens.

Severe Hypertension : Systolic blood pressure ≥ 160 mm Hg \ge 160\text{ mm Hg} ≥ 160 mm Hg or diastolic blood pressure ≥ 100 mm Hg \ge 100\text{ mm Hg} ≥ 100 mm Hg , or hypertension associated with end-organ vascular disease.

Smoking in Older Women : Age ≥ 35 years \ge 35\text{ years} ≥ 35 years smoking ≥ 15 cigarettes per day \ge 15\text{ cigarettes per day} ≥ 15 cigarettes per day (smoking < 15 < 15 < 15 cigarettes/day at age ≥ 35 \ge 35 ≥ 35 is MEC Category 3).

Venous Thromboembolism (VTE) : Current or past personal history of deep vein thrombosis or pulmonary embolism; known inherited or acquired thrombogenic mutations (e.g., Factor V Leiden, Prothrombin gene mutation, Antithrombin III deficiency, Antiphospholipid syndrome).

Ischaemic Heart Disease & Cerebrovascular Disease : Known current or past history of coronary artery disease, stroke, or transient ischaemic attack.

Breast cancer: Current disease contraindicates hormonal contraception. Past disease requires its specific MEC category and oncology advice; it is not the same as current disease.

Complicated Diabetes Mellitus : Diabetes with established microvascular complications (nephropathy, retinopathy, neuropathy) or disease duration > 20 years > 20\text{ years} > 20 years .

Severe Hepatic Impairment : Decompensated cirrhosis, severe acute viral hepatitis, or benign/malignant liver tumours (hepatocellular adenoma or carcinoma).

Prolonged Immobilization : Major surgery with prolonged bed rest.

Early Postpartum : < 6 weeks < 6\text{ weeks} < 6 weeks postpartum if breastfeeding (increases VTE risk and may suppress lactation).

Missed combined pills

Use the Australian product/clinical flowchart for the pill concerned. For a conventional combined pill, more than 48 hours since the previous active pill means a pill has been missed. This differs from a US rule framed as two pills or 48 hours after the next pill was due. Take the most recent missed active pill, continue the pack and use condoms or abstain until seven active pills have been taken consecutively. If the lapse is near the start after a hormone-free interval, assess recent unprotected sex and emergency contraception. If fewer than seven active pills remain, omit the hormone-free interval and start the next active pack. Progestogen-only pills have formulation-specific lateness windows; do not apply combined-pill rules to them.

Emergency Contraception (EC)

Emergency contraception is indicated following unprotected sexual intercourse (UPSI) or potential contraceptive failure to prevent unintended pregnancy.

Primary references (checked 7 October 2026): Australian combined-pill flowchart ; RANZCOG abortion guideline .